Novo Nordisk’s AM833 Shows Early Success In Obesity Trials
Novo Nordisk has unveiled headline results from two clinical trials with a novel once-weekly subcutaneous amylin analogue (AM833) – a Phase II monotherapy trial and a Phase I combination trial…
Share